Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
GHRP-2
EfficacyHigh
Studies5
Participants98
StatusAvailable

GHRP-2

D-alanyl-D-2-naphthylalanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide developed as a second-generation growth hormone secretagogue by Bowers and colleagues in the early 1990s. Also known as pralmorelin in clinical literature, it potently stimulates growth hormone release through GHS-R1a receptor activation. GHRP-2 incorporates D-amino acids for enhanced stability and resistance to enzymatic degradation, making it significantly more potent than earlier analogs like GHRP-6.

Clinical Safety Profile

Reported Side Effects

Transient facial flushing (most common)
Increased appetite and hunger sensations
Mild injection site reactions
Temporary water retention
Fatigue or drowsiness post-injection
Possible tingling sensations in extremities
Mild headaches in some users
Potential blood sugar fluctuations

Side Effect Management (Clinical Trial Data)

Hunger
Common
32.7%
Flushing
Common
18.4%
Headaches
Occasional
12.2%
Water Retention
Infrequent
9.8%
Injection Site Reactions
Infrequent
7.1%

Side Effect Management Strategies

Nausea: Take with food, smaller meals, ginger supplements
Vomiting: Slower dose escalation, anti-emetics if severe
Diarrhea: Adequate hydration, probiotics, bland diet
Constipation: Increase fiber intake, adequate fluids, light exercise

Clinical Safety Metrics

Good
Overall Safety Rating
12.4%
Discontinuation Rate
Research
Approved Status

CONTRAINDICATIONS

Active malignancy or cancer history
Diabetic retinopathy or severe diabetic complications
Pregnancy and breastfeeding
Known hypersensitivity to GHRP-2 or excipients

Medical Disclaimer

GHRP-2 is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Any use should occur only under medical supervision in approved research settings.